‘World’s first malaria vaccine’ proven effective in clinical trial
SEATTLE and LONDON — An experimental GlaxoSmithKline vaccine reduced the risk of clinical malaria infections in African children by 56 percent in a major clinical trial, making it likely to become the world’s first vaccine to protect children against the mosquito-borne disease, Reuters reported.
The trial also found that the vaccine reduced the risk of severe malaria by 47 percent.
Final-stage trial data released on Tuesday showed it gave protection against clinical and severe malaria in five- to 17-month-olds in Africa, where the illness kills hundreds of thousands of children a year.
"These data bring us to the cusp of having the world''s first malaria vaccine," said Andrew Witty, chief executive of the British drugmaker that developed the vaccine along with the nonprofit PATH Malaria Vaccine Initiative (MVI).